Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
In Vitro Diagnostics Cancer Deals

AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza

  • News

Executive Summary

Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

You may also be interested in...



How To Comply With New Requirements For Companion Diagnostics Under IVDR

The regulation of companion diagnostics will be far stricter under the IVDR than the current IVD Regulation. EU life sciences regulatory lawyer Elisabethann Wright provides an overview and explains how companies should prepare for compliance.

Foundation Medicine Obtains FDA Approval For Non Small Cell Lung Cancer Companion Diagnostic

Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.

Guardant Health, Roche’s Foundation Medicine Receive FDA Companion Diagnostic Nods

Roche’s Foundation Medicine still leads Guardant Health in terms of total companion-diagnostic US FDA approvals as both companies announced new PMA supplements.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
In Vitro Diagnostics Cancer Deals
Latest Headlines

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

Postmarket Surveillance Continues To Challenge AI/ML Device Regulators

Q&A: Allyson Mullen On ‘Uncharted Waters’ Of Breakthrough Pathway

See All
UsernamePublicRestriction

Register

MT145307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By